Association of TLR4 gene polymorphisms with sporadic Parkinson’s disease in a Han Chinese population

Neurological Sciences

Volumn 36, Issue 9, 2015, Pages 1659-1665

  Zhao, Jing ^a   Han, Xun ^a,b   Xue, Li ^a   Zhu, Konghua ^a   Liu, Hongxin ^a   Xie, Anmu ^a  

^a QINGDAO UNIVERSITY   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Parkinson s disease (PD); Single nucleotide polymorphisms (SNPs); Toll like receptor 4 (TLR4)

Indexed keywords

TAQ POLYMERASE; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAN CHINESE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SPORADIC PARKINSON DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; GENOTYPING TECHNIQUE; MIDDLE AGED; SEX DIFFERENCE; VERY ELDERLY;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; SEX FACTORS;

EID: 84957436414     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-015-2227-9     Document Type: Article

References (29)

1. Reeve A, Simcox E, Turnbull D (2014) Ageing and Parkinson’s disease: Why is advancing age the biggest risk factor? Ageing Res Rev. doi:10.1016/j.arr.2014.01.004
2. Zhang ZX, Roman GC, Hong Z, Wu CB, Qu QM, Huang JB, Zhou B, Geng ZP, Wu JX, Wen HB, Zhao H, Zahner GE (2005) Parkinson’s disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet 365(9459):595–597. doi:10.1016/s0140-6736(05)17909-4
3. Jellinger KA (2011) Synuclein deposition and non-motor symptoms in Parkinson disease. J Neurol Sci 310(1–2):107–111. doi:10.1016/j.jns.2011.04.012
4. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5(3):235–245. doi:10.1016/s1474-4422(06)70373-8
5. Sung VW, Nicholas AP (2013) Nonmotor symptoms in Parkinson’s disease: expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin 31(3 Suppl):S1–16. doi:10.1016/j.ncl.2013.04.013
6. Gao HM, Hong JS (2008) Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 29(8):357–365. doi:10.1016/j.it.2008.05.002
7. Qian L, Flood PM, Hong JS (2010) Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy. J Neural Transm (Vienna, Austria: 1996) 117(8):971–979. doi:10.1007/s00702-010-0428-1
8. Russo I, Bubacco L, Greggio E (2014) LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease? J Neuroinflamm 11:52. doi:10.1186/1742-2094-11-52
9. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8(4):382–397. doi:10.1016/s1474-4422(09)70062-6
10. Ziakas PD, Prodromou ML, El Khoury J, Zintzaras E, Mylonakis E (2013) The role of TLR4 896 A>G and 1196 C>T in susceptibility to infections: a review and meta-analysis of genetic association studies. PLoS ONE 8(11):e81047. doi:10.1371/journal.pone.0081047
11. Creagh EM, O’Neill LA (2006) TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 27(8):352–357. doi:10.1016/j.it.2006.06.003
12. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, Volpe JJ, Vartanian T (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA 100(14):8514–8519. doi:10.1073/pnas.1432609100
13. Barton GM (2008) A calculated response: control of inflammation by the innate immune system. J Clin Investig 118(2):413–420. doi:10.1172/jci34431
14. Drouin-Ouellet J, Gibrat C, Bousquet M, Calon F, Kriz J, Cicchetti F (2011) The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. J Neuroinflamm 8:137. doi:10.1186/1742-2094-8-137
15. Zakeri S, Pirahmadi S, Mehrizi AA, Djadid ND (2011) Genetic variation of TLR-4, TLR-9 and TIRAP genes in Iranian malaria patients. Malaria J 10:77. doi:10.1186/1475-2875-10-77
16. Noelker C, Morel L, Lescot T, Osterloh A, Alvarez-Fischer D, Breloer M, Henze C, Depboylu C, Skrzydelski D, Michel PP, Dodel RC, Lu L, Hirsch EC, Hunot S, Hartmann A (2013) Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 3:1393. doi:10.1038/srep01393
17. Kutikhin AG (2011) Impact of Toll-like receptor 4 polymorphisms on risk of cancer. Hum Immunol 72(2):193–206. doi:10.1016/j.humimm.2010.11.003
18. Yu JT, Miao D, Cui WZ, Ou JR, Tian Y, Wu ZC, Zhang W, Tan L (2012) Common variants in toll-like receptor 4 confer susceptibility to Alzheimer’s disease in a Han Chinese population. Curr Alzheimer Res 9(4):458–466
19. Reindl M, Lutterotti A, Ingram J, Schanda K, Gassner C, Deisenhammer F, Berger T, Lorenz E (2003) Mutations in the gene for toll-like receptor 4 and multiple sclerosis. Tissue Antigens 61(1):85–88
20. Chen YC, Yip PK, Huang YL, Sun Y, Wen LL, Chu YM, Chen TF (2012) Sequence variants of toll like receptor 4 and late-onset Alzheimer’s disease. PLoS ONE 7(12):e50771. doi:10.1371/journal.pone.0050771
21. Singh K, Singh VK, Agrawal NK, Gupta SK, Singh K (2013) Association of Toll-like receptor 4 polymorphisms with diabetic foot ulcers and application of artificial neural network in DFU risk assessment in type 2 diabetes patients. Biomed Res Int 2013:318686. doi:10.1155/2013/318686
22. Huang L, Yuan K, Liu J, Ren X, Dong X, Tian W, Jia Y (2014) Polymorphisms of the TLR4 gene and risk of gastric cancer. Gene 537(1):46–50. doi:10.1016/j.gene.2013.12.030
23. Daniel SE, Lees AJ (1993) Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 39:165–172
24. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427–442
25. Peterson LJ, Flood PM (2012) Oxidative stress and microglial cells in Parkinson’s disease. Mediators Inflamm 2012:401264. doi:10.1155/2012/401264
26. Lee MS, Kim YJ (2007) Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu Rev Biochem 76:447–480. doi:10.1146/annurev.biochem.76.060605.122847
27. Trotta T, Porro C, Calvello R, Panaro MA (2014) Biological role of Toll-like receptor-4 in the brain. J Neuroimmunol 268(1–2):1–12. doi:10.1016/j.jneuroim.2014.01.014
28. Beraud D, Twomey M, Bloom B, Mittereder A, Ton V, Neitzke K, Chasovskikh S, Mhyre TR, Maguire-Zeiss KA (2011) Alpha-synuclein alters Toll-like receptor expression. Front Neurosci 5:80. doi:10.3389/fnins.2011.00080
29. Beraud D, Maguire-Zeiss KA (2012) Misfolded alpha-synuclein and Toll-like receptors: therapeutic targets for Parkinson’s disease. Parkinsonism Relat Disord 18(Suppl 1):S17–20. doi:10.1016/s1353-8020(11)70008-6